An engineered probiotic designed to treat a metabolic disease enters clinical trials.
References
Isabella, V. et al. Nat. Biotechnol. 36, 857–864 (2018).
Bermúdez-Humarán, L.G. et al. J. Immunol. 175, 7297–7302 (2005).
Lagenaur, L.A. et al. Mucosal Immunol. 4, 648–657 (2011).
Duan, F.F., Liu, J.H. & March, J.C. Diabetes 64, 1794–1803 (2015).
Durrer, K.E., Allen, M.S. & Hunt von Herbing, I. PLoS One 12, e0176286 (2017).
Whelan, R.A. et al. Mol. Ther. 22, 1730–1740 (2014).
Chen, Z. et al. J. Clin. Invest. 124, 3391–3406 (2014).
Plovier, H. et al. Nat. Med. 23, 107–113 (2017).
Quévrain, E. et al. Gut 65, 415–425 (2016).
Hamady, Z.Z. et al. Inflamm. Bowel Dis. 17, 1925–1935 (2011).
Limaye, S.A. et al. Cancer 119, 4268–4276 (2013).
Motta, J.P. et al. Sci. Transl. Med. 4, 158ra144 (2012).
Bermúdez-Humarán, L.G. et al. Microb. Cell Fact. 14, 26 (2015).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Bermúdez-Humarán, L., Langella, P. Live bacterial biotherapeutics in the clinic. Nat Biotechnol 36, 816–818 (2018). https://doi.org/10.1038/nbt.4248
Published:
Issue Date:
DOI: https://doi.org/10.1038/nbt.4248
- Springer Nature America, Inc.